Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2019 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors.
Choo JRE, Jan YH, Ow SGW, Wong A, Lee MX, Ngoi N, Yadav K, Lim JSJ, Lim SE, Chan CW, Hartman M, Tang SW, Goh BC, Tan HL, Chong WQ, Yvonne ALE, Chan GHJ, Chen SJ, Tan KT, Lee SC. Choo JRE, et al. Target Oncol. 2022 May;17(3):355-368. doi: 10.1007/s11523-022-00886-x. Epub 2022 Jun 14. Target Oncol. 2022. PMID: 35699834 Free PMC article.
Retracted: Obestatin Plays Beneficial Role in Cardiomyocyte Injury Induced by Ischemia-Reperfusion In Vivo and In Vitro.
Zhang Q, Dong XW, Xia JY, Xu KY, Xu ZR. Zhang Q, et al. Med Sci Monit. 2023 Oct 4;29:e942752. doi: 10.12659/MSM.942752. Med Sci Monit. 2023. PMID: 37791420 Free PMC article.
The Editors of Medical Science Monitor wish to inform you that the above manuscript has been retracted from publication due to concerns with the credibility and originality of the study, the manuscript content, and the Figure images. Reference: Qin Zhang, Xin-wei Dong, Jia …
The Editors of Medical Science Monitor wish to inform you that the above manuscript has been retracted from publication due to concerns with …
[A comparison of efficacy and safety between Chinese generic imatinib versus branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase: a single-center prospective cohort study].
Shi HX, Qin YZ, Lai YY, Huang XJ, Jiang Q. Shi HX, et al. Zhonghua Nei Ke Za Zhi. 2016 Dec 1;55(12):922-926. doi: 10.3760/cma.j.issn.0578-1426.2016.12.003. Zhonghua Nei Ke Za Zhi. 2016. PMID: 27916045 Chinese.
Methods: Patients with newly diagnosed CML-CP were enrolled and assigned to receive either Xinwei or Glivec at an initial dose of 400 mg/d according to patients' financial capability. ...Conclusions: Early hematological, cytogenetic and molecular responses between Xinwe …
Methods: Patients with newly diagnosed CML-CP were enrolled and assigned to receive either Xinwei or Glivec at an initial dose of 400 …
[Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL, Yu L, Qin YZ, Shi HX, Lai YY, Hou Y, Huang XJ, Jiang Q. Dou XL, et al. Zhonghua Xue Ye Xue Za Zhi. 2019 Nov 14;40(11):924-931. doi: 10.3760/cma.j.issn.0253-2727.2019.11.008. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31856442 Free PMC article. Chinese.
Methods: Frontline group: Data of adults with newly diagnosed CML-CP receiving Chinese generic imatinib (Xinwei()) or branded imatinib (Glivec()) between October 2013 and August 2018 were retrospectively collected and analyzed. ...
Methods: Frontline group: Data of adults with newly diagnosed CML-CP receiving Chinese generic imatinib (Xinwei()) or branded imatini …